Search Results - "Seokuee Kim"
-
1
Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
Published in British journal of clinical pharmacology (01-07-2022)“…Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is…”
Get full text
Journal Article -
2
Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Published in Gut and liver (01-01-2023)“…Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal…”
Get full text
Journal Article -
3
Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
Published in Frontiers in pharmacology (11-11-2021)“…Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of…”
Get full text
Journal Article -
4
Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
Published in Pharmaceutics (16-09-2021)“…This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of tegoprazan and to predict the drug–drug interaction (DDI) potential between…”
Get full text
Journal Article -
5
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
Published in Drug design, development and therapy (01-01-2017)“…MB12066 is a molecule derived from -lapachone that shown effects on obesity in previous studies. The present studies were conducted to evaluate the…”
Get full text
Journal Article -
6
Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Published in Gut and liver (30-01-2023)“…Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively…”
Get full text
Journal Article -
7
Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Published in Gut and liver (30-01-2023)“…Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively…”
Get full text
Journal Article -
8
Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Published in Gut and liver (30-01-2023)“…Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively…”
Get full text
Journal Article -
9
Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Published in Gut and liver (30-01-2023)“…Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively…”
Get full text
Journal Article -
10
Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study
Published in Clinical therapeutics (01-11-2019)“…Celecoxib is a selective cyclooxygenase-2 inhibitor widely used in patients with osteoarthritis and rheumatoid arthritis. Recently, nonclinical data on the…”
Get full text
Journal Article -
11
Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects
Published in Journal of clinical pharmacology (01-07-2021)“…This clinical trial was conducted to evaluate the pharmacokinetics and pharmacodynamics of tegoprazan when coadministered with amoxicillin/clarithromycin in…”
Get full text
Journal Article -
12
Evaluation of pharmacokinetic drugdrug interaction between tegoprazan and clarithromycin in healthy subjects
Published in Translational and clinical pharmacology (01-06-2023)“…Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens…”
Get full text
Journal Article -
13
Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients
Published in Bone marrow transplantation (Basingstoke) (01-02-2019)“…Fludarabine is used as a common component of conditioning regimens for haematopoietic stem cell transplantation (HSCT). However, knowledge regarding the…”
Get full text
Journal Article -
14
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors
Published in Expert opinion on investigational drugs (01-09-2020)“…We evaluated the tolerability, pharmacokinetics (PK) and preliminary efficacy of KML001, an oral trivalent arsenical, as a monotherapy in patients with…”
Get more information
Journal Article -
15
Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01-02-2019)“…Objective This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and safety properties of the test (CJ-40001) and reference (NESP ® ) versions of…”
Get full text
Journal Article -
16
Comparison of the pharmacokinetics and tolerability of montelukast/levocetirizine administered as a fixed-dose combination and as separate tablets
Published in International journal of clinical pharmacology and therapeutics (01-09-2018)“…A novel fixed-dose combination (FDC) capsule of 10/5 mg of montelukast/levocetirizine may lead to better compliance than two separate tablets taken together…”
Get full text
Journal Article -
17
Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
Published in Translational and clinical pharmacology (01-06-2023)“…Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens…”
Get full text
Journal Article -
18
Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
Published in BioMed research international (01-01-2019)“…Purpose. We evaluated potential drug-drug interactions between cilostazol and simvastatin, both CYP3A substrates, in healthy subjects. Methods. An open-label,…”
Get full text
Journal Article -
19
Pharmacokinetics and safety of a single dose of the novel necrosis inhibitor LC28‐0126 in healthy male subjects
Published in British journal of clinical pharmacology (01-06-2017)“…Aims A novel necrosis inhibitor, LC28‐0126, is expected to have a cellular protective effect from ischaemic reperfusion injury in acute myocardial infarction…”
Get full text
Journal Article -
20
Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study
Published in Clinical pharmacology in drug development (01-04-2020)“…The objective of study was to compare the pharmacokinetic and safety profiles of a fixed‐dose combination (FDC) formulation of 5/160/20 mg…”
Get full text
Journal Article